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“Global public goods favor the mechanism of public informa-
tion resources and free and open communication therein.
Global public goods once produced should benefit all.  Like a
clean environment, knowledge about human health has no
one institutional home.  Like the gene pool at the level of the
species being considered the common heritage of humanity,
so genomic databases while recognizing the initial contribu-
tion of individual participants and of individual researchers or
commercial investors should also account for the needs of
present and future generations and foster and promote inter-
national collaboration.”1
All signs point to the potential for the Human GenomeProject to provide tools for the translation of ge-nomic knowledge to clinical diagnosis, with implica-
tions for every level of the health care system.2 Indeed,
“[g]enomics is inspiring the development of very large longi-
tudinal cohort studies and even studies of entire populations
to establish repositories of biological materials (‘biobanks’)
for discovery and characterization of genes associated with
common diseases.”3 With these “biobanks,” an important
advance in human genetics will be the identification and
characterization of numerous common genetic variants at
specific loci that increase or decrease the risks for various
diseases singly and in combination with other genes and
with various chemical, physical, infectious, pharmacologic
and social factors. Yet, when applied to such population
studies and to the ensuing accompanying genomic data-
bases, current consent and privacy mechanisms may limit
the use of these biobanks for public health research.4,5
Although the publicly available sequence map of the hu-
man genome was preceded by other international collabora-
tive efforts6,7 such as the mutation database initiative and,
more recently, by the International Haplotype project, these
essential scientific building blocks of understanding raise
only limited privacy concerns.8,9 More problematic are the pri-
vacy issues facing population banks that study genotype and
phenotype interaction.10 Currently still under construction,
these human genetic research databases will constitute an
immense public resource.11
Coupling human genomic databases with databases of
pathogens yields the promise of a strengthened scientific ba-
sis for the primary and secondary prevention of disease. Com-
bined with understanding of environmental factors, it will
eventually provide the basis for programs of health promotion
and disease prevention, when public health powers permit.
Norms for the emergence of a new paradigm for public
health interventions must be informed by issues beyond the
legal and ethical parameters of autonomy and privacy.12 In-
deed, the fundamental reason why contemporary medical
ethics has so little to say about public health is that its focus
on individual autonomy suggests that all compulsion for the
sake of health is wrong. Yet “many public health measures
must be compulsory if they are to be effective.”13,14 Thinking
at the level of populations or groups requires a vetting of cur-
rent ethical and legal principles and the development of a
concept of the public good or of “common” goods.15
Privacy directives in Europe, laws in the United States and
guidelines in Canada often treat personal genetic information as
distinct from medical and personal data.1 Classical approaches
to public health are based on the model of epidemic control,
and the rise of autonomy and privacy legislation in the last
decades has left little room for ongoing surveillance.13 In short,
genomic databases are pulled under this “genetic privacy” um-
brella even when they are limited to the study of genomic varia-
tion (e.g., HapMap [www.hapmap.org], CARTaGENE
[www.cartagene.qc.ca]). Such databases can range from de-
scriptions of sequences, to annotated and curated databases, to
disease-specific and, finally, longitudinal population databases
such as the United Kingdom biobank (www.biobank.ac.uk).
While basically oriented toward the building of scientific infra-
structures and resources on genomic variation rather than indi-
vidual disease-oriented studies on specific cohorts, there is no
doubt that their potential usefulness for public health surveil-
lance of genomic susceptibility to diseases is immense. 
The concept of public goods has its roots in the 18th cen-
tury. Hume coined the expression “providing for the ‘com-
mon good’” in his Treatise on Human Nature (1739). Two
main qualities exemplify “pure” public goods: its benefits are
nonrivalrous in consumption (i.e., one person or group’s use
does not preclude another person or group’s use of a public
good) and nonexcludable (i.e., no one can be excluded from
benefiting from a public good). Likewise, the “benefits of epi-
demiological intelligence are nondivisible for all countries.”15
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Ultimately, humanity as a whole should be the beneficiary of
global public goods. The qualifying mark of a global public
good is that it meets the needs of present generations without
jeopardizing those of future generations.15 It is the latter quality
together with those of non-rivalry and non-excludability that led
the HUGO (The Human Genome Organization) Ethics Com-
mittee in its 2002 Statement on Human Genomic Databases16 to
take the position on primary genomic sequences that: 
1. Human genomic databases are global public goods. (a) Knowl-
edge useful to human health belongs to humanity. (b) Human ge-
nomic databases are a public resource. (c) All humans should share
in and have access to the benefits of databases.16
Policy development in this area must take contextual and
cultural factors into consideration.17 To avoid untoward ef-
fects, genetic research that identifies differential risks in pop-
ulations requires special consideration before they are incor-
porated into laws, regulations or public health practices.18,19
One of the underlying values of Canada’s 2004 proposal for
health protection renewal legislation is to “include public en-
gagement in the decision-making process.” Both collective
and individual rights and interests are at stake in creating or
accessing genomic databases for public health research.20 It
is also this “population focus [that] distinguishes public
health from the clinical enterprise that is governed by the
Hippocratic imperative with its focus on the individual pa-
tient.”6 It would be shortsighted indeed to fail to develop
ethics for public health genomics, for the public funding of
resources such as large genomic databases is ultimately
premised on their usefulness in the public interest.
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